AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE
Clinical trials for AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE explained in plain language.
Never miss a new study
Get alerted when new AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE trials appear
Sign up with your email to follow new studies for AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Alzheimer's agitation drug safety study halted early
Disease control TerminatedThis study looked at the long-term safety of a drug called AXS-05 for treating agitation in people with Alzheimer's disease. It included 139 participants who had already completed earlier studies. The main goal was to track side effects over time. The study was terminated early, …
Matched conditions: AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Alzheimer's agitation drug study halted early
Symptom relief TerminatedThis study tested a drug called AVP-786 to see if it could safely reduce agitation in people with Alzheimer's disease over a long period. It was an extension of earlier studies and included over 1,100 participants. The main goal was to check for side effects, but the study was te…
Matched conditions: AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated May 15, 2026 11:56 UTC